Journals / MN Oftalmoloji / 2021 / Cilt: 28 - Sayı: 4

Development of Toxic Keratopathy Due to Fortified Topical Antibiotic Treatment

Güçlendirilmiş Topikal Antibiyotik Tedavisine Bağlı Toksik Keratopati Gelişimi

Pages
243–246
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

The duration of the treatment is important when using the fortified antibiotic treatment and unpreserved single-drug therapy is suggested in appropriate cases.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To evaluate the development of toxic keratopathy in patients due to fortified topical antibiotic treatment.
📊
Key Findings & Data:The treatment was continued with topical 0,5% moxifloxacin according to the course of the disease.
💡
Conclusion & Impact:The duration of the treatment is important when using the fortified antibiotic treatment and unpreserved single-drug therapy is suggested in appropriate cases.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To evaluate the development of toxic keratopathy in patients due to fortified topical antibiotic treatment. Material and Method: The records of patients, who were hospitalized for various diagnoses and received fortified topical antibiotic treatment, were investigated. The treatment was continued with topical 0,5% moxifloxacin according to the course of the disease. Fortified topical antibiotic treatment time, the initial time and the duration of toxic keratopathy, the time of switching the therapy to unpreserved topical single drug treatment were evaluated. Results: 46 patients with toxic keratopathy were recruited. Topical vancomycin and ceftazidime were used in 36 patients and topical gentamycin and cefazoline were used in 10 patients. The mean duration of topical antibiotic drop use was 10,4±6,0 day, the mean initial time of toxic keratopathy was 4,8±2,2 day after the beginning of treatment. The mean recovery time was 13,5±7,0 days after the beginning. The mean duration of toxic keratopathy was 8,6±6,4 days. The mean time of switching the treatment to a single drug was 11,1±5,9 days after the beginning of treatment. There was a positive correlation between the duration of fortified topical antibiotic drop use and the duration of toxic keratopathy (p=0,001, r=0,491). Conclusion: The longer the use of fortified topical drops, the longer the duration of toxic keratopathy and the recovery began after switching the treatment to single drop use. The duration of the treatment is important when using the fortified antibiotic treatment and unpreserved single-drug therapy is suggested in appropriate cases.

Özet

Amaç: Güçlendirilmiş topikal antibiyotikli damla tedavisi uygulanmış hastalarda toksik keratopati gelişimini değerlendirmek. Gereç ve Yöntem: Kliniğimizde çeşitli tanılarla yatarak tedavi görmüş ve güçlendirilmiş topikal damla tedavisi alan hastaların dosyaları geriye dönük olarak incelendi. Hastalığın seyrine göre tedaviye koruyucusuz topikal %0,5 moksifloksasin ile devam edildi. Güçlendirilmiş topikal ilaç tedavi süresi, toksik keratopati başlama zamanı, süresi, koruyucusuz topikal tek ilaç tedavisine geçiş zamanı değerlendirildi. Bulgular: Çalışmaya toksik keratopati gelişmiş 46 hasta alındı. Hastaların 36’sında topikal vankomisin ve seftazidim kullanıldığı, 10’unda topikal gentamisin ve sefazolin kullanıldığı görüldü. Ortalama güçlendirilmiş topikal damla kullanım süresi 10,4±6,0 gün, toksik keratopati başlama zamanı tedavinin 4,8±2,2. günü, iyileşme zamanı ise 13,5±7,0. günü idi. Ortalama toksik keratopati süresi 8,6±6,4 gündü. Tekli ilaç tedavisine geçiş zamanı ortalama 11,1±5,9. gün idi. Güçlendirilmiş topikal damla kullanımı süresi ile toksik keratopati süresi arasında pozitif korelasyon tespit edildi (p=0,001, r= 0,491). Sonuç: Güçlendirilmiş topikal damla kullanım süresi arttıkça toksik keratopati süresi de artmakta tekli ilaç tedavisine geçişin ardından iyileşme başlamaktadır. Güçlendirilmiş antibiyotik tedavisi uygularken tedavi süresi önemli olmaktadır ve uygun olgularda koruyucusuz tek ilaç tedavisi önerilir.

🔖

Cite This Article

ÇAKIR, B., SÖNMEZOĞLU, B., AKSOY, N. Ö., DOĞAN, E. (2021). Development of Toxic Keratopathy Due to Fortified Topical Antibiotic Treatment. MN Oftalmoloji, Cilt: 28 - Sayı: 4, 243–246. https://ajindex.com/articles/406067

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (1)

  1. Chen Y. Le Q, Hong J. Gong L, Xu J. In vivo confocal microscopy of toxic keratopathy. Eye (Lond). 2017;31(1):140-7. doi:10.1038/eye.2016.213 2. Fraunfelder FW. Corneal toxicity from topical ocular and systemic medications. Cornea. 2006;25(10):1133-8. 3. Schwab IR. Abbott RL. Toxic ulcerative keratopathy. An unrecognized problem. Ophthalmology. 1989;96(8):1187-93. 4. Chappelet MA. Bernheim D. Chiquet C. Aptel F. Effect of a New Matrix Therapy Agent in Persistent Epithelial Defects After Bacterial Keratitis Treated With Topical Fortified Antibiotics. Cornea. 2017;36(9):1061-8. doi: 10.1097/ICO.000000000000 1261. 5. Robinson A. Kremer I. Avisar R. Gaton D. Savir H. Yassur Y. The combination of topical ceftazidime and aminoglycosides in the treatment of refractory pseudomonal keratitis. Graefes Arch Clin Exp Ophthalmol. 1999;237(3):177-80. doi: 10.1007/ s00417 0050215. 6. Dikmetaş Ö. Deniz Y. Kocabeyoğlu S. Başol M. İrkeç M. The Value of Fortified Aminoglycoside/ Cephalosporin Treatment as First-Line Treatment and in Fluoroquinolone-Resistant Bacterial Keratitis. T J Ophthalmol. 2020;50(5):258-63. doi: 10.4274/tjo. galenos. 2020.37346. 7. McDonald EM. Ram FS. Patel DV. McGhee CN. Topical antibiotics for the management of bacterial keratitis: an evidence-based review of high quality randomised controlled trials. Br J Ophthalmol. 2014;98(11):1470-7. doi:10.1136/bjophthalmol2013-304660. 8. Ofloxacin monotherapy for the primary treatment of microbial keratitis: a double-masked, randomized, controlled trial with conventional dual therapy. The Ofloxacin Study Group. Ophthalmology. 1997;104(11):1902-9. 9. Hyndiuk RA. Eiferman RA. Caldwell DR. et al. Comparison of ciprofloxacin ophthalmic solution 0.3% to fortified tobramycincefazolin in treating bacterial corneal ulcers. Ciprofloxacin Bacterial Keratitis Study Group. Ophthalmology. 1996;103(11): 1854-62; discussion 1862-3. doi: 10.1016/s0161-6420(96)30416- 8. 10. Panda A. Ahuja R. Sastry SS. Comparison of topical 0.3% ofloxacin with fortified tobramycin plus cefazolin in the treatment of bacterial keratitis. Eye (Lond). 1999;13 (Pt 6):744-7. doi: 10. 1038/eye. 1999.220. 11. Lin N. Gong XM. Xie QJ. Shao MR. Study in cytotoxicity of gentamycin to corneal epithelium and endothelium in tissue culture. Yan Ke Xue Bao. 1989;5(1-2):32-5. PMID: 2485741. 12. Fernández-Ferreiro A. González-Barcia M. Gil-Martínez M. et al. Evaluation of the in vitro ocular toxicity of the fortified antibiotic eye drops prepared at the Hospit